Llwytho...
PARPi after PARPi in epithelial ovarian cancer
The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 li...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Gynecol Oncol Rep |
|---|---|
| Prif Awduron: | , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elsevier
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7840844/ https://ncbi.nlm.nih.gov/pubmed/33537389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100699 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|